Barclays PLC Purchases 13,054 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)

Barclays PLC boosted its position in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 66.6% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 32,664 shares of the biotechnology company’s stock after purchasing an additional 13,054 shares during the period. Barclays PLC owned about 0.22% of Anika Therapeutics worth $806,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Eastern Bank bought a new position in shares of Anika Therapeutics during the 3rd quarter valued at approximately $28,000. Quest Partners LLC grew its position in shares of Anika Therapeutics by 115.8% during the 3rd quarter. Quest Partners LLC now owns 6,904 shares of the biotechnology company’s stock valued at $171,000 after acquiring an additional 3,705 shares during the period. Atria Investments Inc bought a new position in shares of Anika Therapeutics during the 3rd quarter valued at approximately $218,000. SG Americas Securities LLC grew its position in shares of Anika Therapeutics by 43.1% during the 3rd quarter. SG Americas Securities LLC now owns 9,485 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 2,858 shares during the period. Finally, Cornercap Investment Counsel Inc. bought a new position in shares of Anika Therapeutics during the 3rd quarter valued at approximately $238,000. 91.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently commented on ANIK shares. Barrington Research dropped their price target on shares of Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. StockNews.com cut shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 4th.

Anika Therapeutics Stock Performance

Anika Therapeutics stock opened at $16.02 on Thursday. The firm’s fifty day moving average price is $16.81 and its 200-day moving average price is $22.25. The stock has a market cap of $234.63 million, a P/E ratio of -2.41 and a beta of 0.90. Anika Therapeutics, Inc. has a fifty-two week low of $15.40 and a fifty-two week high of $29.11.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.